Table 3.

Results of independent MAGPIE analyses on individual pathways in each tumor site

Sitea	# of tumors	RTK-RAS			PI3K			Wnt
		Mut freq	Driver freq	p val	Mut freq	Driver freq	p val	Mut freq	Driver freq	p val
BRCA	987	0.217	0.090	0.017	0.475	0.400	<0.001	0.098	0.039	0.266
LGG	520	0.221	0.115	0.033	0.187	0.095	0.032	0.056	0.034	0.029
UCEC	508	0.614	0.385	<0.001	0.904	0.719	<0.001	0.575	0.309	<0.001
LUAD	503	0.809	0.632	<0.001	0.400	0.205	0.002	0.314	0.140	0.002
HNSC	489	0.409	0.177	0.024	0.317	0.246	0.051	0.225	0.093	0.011
THCA	486	0.728	0.723	<0.001	0.047	0.008	0.599	0.037	0.010	0.249
PRAD	477	0.117	0.069	0.370	0.094	0.044	0.313	0.094	0.062	0.004
LUSC	464	0.597	0.213	0.356	0.407	0.221	0.186	0.349	0.157	0.288
BLCA	399	0.684	0.398	<0.001	0.451	0.194	0.435	0.291	0.145	0.049
SKCM	365	0.942	0.895	<0.001	0.504	0.228	0.005	0.553	0.188	0.014
KIRC	353	0.235	0.080	0.317	0.195	0.054	0.909	0.079	0.049	0.129

^aTCGA disease codes and abbreviations: BRCA, breast cancer; LGG, lower grade glioma; UCEC, uterine corpus endometrial carcinoma; LUAD, lung adenocarcinoma; HNSC, head and neck squamous cell carcinoma; THCA, papillary thyroid carcinoma; PRAD: Prostate adenocarcinoma; LUSC, lung squamous cell carcinoma; BLCA, urothelial bladder cancer; SKCM, cutaneous melanoma; KIRC: clear cell kidney carcinoma.